Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE study of PF-04523655 with or without ranibizumab in diabetic macular edema
2011-004157-66Phase 2Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- Dec 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-04523655 and ranibizumab in diabetic macular edema (DME) (4 arms), sponsored by Quark Pharmaceuticals. Started Dec 2011; status: completed.
02
Drugs
PF-04523655ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2011-004157-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004157-66.